EUVIMEDEUVIMED entdecken
Crossref

New therapeutic targets in the management of advanced gastric cancer

Paula Gomila Pons, Carmen Blanco Abad, Roberto Pazo-Cid

Academia Oncology · 2024

DOI: 10.20935/acadonco7447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academia Oncology, 2024. Verfasst von Paula Gomila Pons und 2 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of advanced gastric cancer remains challenging due to its late diagnosis and aggressive nature. HER2 inhibitors like trastuzumab deruxtecan (T-DXd) show significant efficacy in HER2-positive gastric cancer. Drugs targeting claudin 18.2 such as zolbetuximab and drugs targeting fibroblast growth factor 2b such as bemarituzumab have shown promising results in clinical trials. Immune checkpoint inhibitors such as pembrolizumab and nivolumab exhibit striking efficacy in select patient cohorts, particularly those exhibiting microsatellite instability. This review highlights the transformative potential of emerging therapeutic targets in the fight against advanced gastric cancer, emphasizing the need for ongoing innovation and clinical research.

Zitieren

APA

Pons, P. G., Abad, C. B., & Pazo-Cid, R. (2024). New therapeutic targets in the management of advanced gastric cancer. Academia Oncology. https://doi.org/10.20935/acadonco7447

Vancouver

Pons PG, Abad CB, Pazo-Cid R. New therapeutic targets in the management of advanced gastric cancer. Academia Oncology. 2024. doi:10.20935/acadonco7447

BibTeX
@article{Pons2024,
  author = {Pons, Paula Gomila and Abad, Carmen Blanco and Pazo-Cid, Roberto},
  title = {New therapeutic targets in the management of advanced gastric cancer},
  journal = {Academia Oncology},
  year = {2024},
  doi = {10.20935/acadonco7447}
}
Kostenlos starten →